PYPD Polypid

PolyPid to Report First Quarter 2023 Financial Results and Operational Highlights on May 10, 2023

PolyPid to Report First Quarter 2023 Financial Results and Operational Highlights on May 10, 2023

PETACH TIKVA, Israel, April 26, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its first quarter 2023 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 10, 2023. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.

To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question of management, the Company recommends listening via the webcast.

Conference Call Dial-In & Webcast Information:

Date: Wednesday, May 10, 2023
Time:8:30 AM Eastern Time
Conference Call:
Webcast:

About PolyPid

 (Nasdaq: ) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit  and follow us on  and .

References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

Contacts: 



PolyPid Ltd.

Ori Warshavsky

COO – US

908-858-5995

Investors:

Brian Ritchie

LifeSci Advisors

212-915-2578

 



EN
26/04/2023

Underlying

PYPDPolypid

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Polypid

 PRESS RELEASE
Free
PYPD POLYPID

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA PolyPid Submits First Modules as Part of Rolling NDA Review; Completion expected in Second Quarter of 2026  U.S. Commercialization Partnership Negotiations on Track PETACH TIKVA, Israel, March 31, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that it has initiated a New Drug Application (“NDA”) submission to the U.S. Food and Drug Administra...

March 31, 2026 1 EN
 PRESS RELEASE
Free
PYPD POLYPID

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Ap...

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀’s New Drug Application FDA Grants $4.3 Million Small Business Waiver, Enabling Focus on Commercialization Preparations Company On Track to Initiate NDA Submission by the End of this Month PETACH TIKVA, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that the U.S. Food and Drug Administration (FDA) has granted a small busin...

March 17, 2026 1 EN
 PRESS RELEASE
Free
PYPD POLYPID

PolyPid Announces Participation in Upcoming Investor Conferences

PolyPid Announces Participation in Upcoming Investor Conferences PETACH TIKVA, Israel, Feb. 25, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that senior management will participate in two upcoming investor conferences taking place during March 2026. Citizens 2026 Life Sciences Conference Date: March 10, 2026 at 1:40 pm ETLocation: Eden Roc Miami Beach, Miami Beach, FLFormat: Fireside chatWebca...

February 25, 2026 1 EN
 PRESS RELEASE
Free
PYPD POLYPID

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-...

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results The Company is in Advanced Stages of Commercial U.S. Partnership Discussions for D-PLEX₁₀₀ Positive FDA Pre-NDA Feedback Supports Rolling NDA Review; Submission Expected to Begin by the End of the First Quarter of 2026 Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Feb. 11, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiv...

February 11, 2026 1 EN
 PRESS RELEASE
Free
PYPD POLYPID

PolyPid to Report Fourth Quarter 2025 Financial Results and Operationa...

PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026 PETACH TIKVA, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on b...

January 28, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch